Novel antibody therapy in acute lymphoblastic leukemia

Current Hematologic Malignancy Reports

Volumn 9, Issue 2, 2014, Pages 165-173

  Kochuparambil, Samith T ^a   Litzow, Mark R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Acute lymphoblastic leukemia; Anti CD22 antibody; Bi specific T cell engager (BiTE) antibody; Blinatumomab; CD20 antibody; Chemotherapy; Chimeric receptor antigen (CAR) therapy; Epratuzumab; Inotuzumab ozogamicin; Monoclonal antibodies; Rituximab

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BL 22; BLINATUMOMAB; CHIMERIC ANTIGEN RECEPTOR; COMBOTOX; EPRATUZUMAB; EPRATUZUMAB TETRAXETAN YTTRIUM Y 90; INOTUZUMAB OZOGAMICIN; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; MOXETUMOMAB PASUDOTOX; RITUXIMAB; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CELL THERAPY; DISEASE FREE SURVIVAL; HUMAN; LEUKEMIA RELAPSE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RADIOIMMUNOTHERAPY; RECURRENCE FREE SURVIVAL; ADULT; CLINICAL TRIAL (TOPIC); IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84903631214     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-014-0202-9     Document Type: Article

References (50)

1. Jemal A, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106-30.
2. Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009;113(7):1408-11.
3. Pui C-H, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-78. (Pubitemid 43076714)
4. Rowe JM, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760-7. (Pubitemid 41739010)
5. Gökbuget N, Hoelzer D. Novel antibody-based therapy for acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2006;19(4):701-13. (Pubitemid 44418029)
6. Thomas DA, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106(7):1569-80.
7. Thomas DA, Kantarjian H, Faderl S, et al. Outcome after frontline therapy with the modified hyper-CVAD regimen with or without rituximab for de novo acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) Abst 2931. In: ASH Annual Meeting; 2008.
8. Rizzieri DA, Johnson J, Byrd JC, et al. Efficacy and toxicity of rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or Burkitt-like leukemia/lymphoma: Cancer and Leukemia Group B (CALGB) study 10002 Abst 858. In: ASH Annual Meeting; 2010.
9. Kantarjian H, et al. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(31):3876-83.
10. FitzGerald DJ, et al. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res. 2011;71(20):6300-9.
11. Coiffier B, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d ' Etudes des Lymphomes de l ' Adulte. Blood. 2010;116(12):2040-5.
12. Robak T, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1756-65.
13. Dworzak MN, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood. 2008;112(10):3982-8.
14. Thomas DA, et al. Chemoimmunotherapy with a modified hyper- CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3880-9.
15. Wierda WG, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1749-55.
16. Jabbour E,HagopK,O'Brien S. Phase II study of the Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive acute lymphoblastic leukemia (ALL) Abst 2664. In: ASH Annual Meeting; 2013.
17. Nagorsen D, et al. Blinatumomab: a historical perspective. Pharmacol Ther. 2012;136(3):334-42.
18. Tibes R, KeatingMJ, Faderl S. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006;106(12):2645-51.
19. Bargou R, et al. Tumor regression in cancer patients by very low doses of a Tcell-engaging antibody. Science. 2008;321(5891):974-7.
20. Topp MS, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120(26):5185-7.
21. Topp MS, Goekbuget N, Zugmaier G. Anti-CD19 BiTE blinatumomab induces high complete remission rate and prolongs overall survival in adult patients with relapsed/refractory Bprecursor acute lymphoblastic leukemia (ALL) Abst 670. In: ASH Annual Meeting; 2012.
22. Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003;9(10):3982S-90.
23. Leonard JP, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol. 2003;21(16):3051-9. (Pubitemid 46606284)
24. Raetz EA, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a children's oncology group pilot study. J Clin Oncol. 2008;26(22):3756-62.
25. Raetz AE, Cairo M, Borowitz MJ, et al. Reinduction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL) in children, adolescents and young adults: results from Children 's Oncology Group (COG) study ADVL04P2. Abst 573. In: ASH Annual Meeting; 2011.
26. Advani A, McDonough S, Coutre S, et al. Southwest Oncology Group study S0910: a phase 2 trial of clofarabine/ cytarabine/ epratuzumab for relapsed/ refractory acute lymphocytic leukemia, Abs#2603. In: ASH Annual Meeting; 2012.
27. Keating MJ, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10):3554-61. (Pubitemid 34534522)
28. Matthews D, et al. Development of amarrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 1995;85(4):1122-31.
29. Lozanski G, et al. Quantitative measurement of CD52 expression and alemtuzumab binding in adult acute lymphoblastic leukemia (ALL) Abst:2386. In: ASH Annual conference; 2007.
30. Stock W, Sanford S. Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): final phase I results of a Cancer and Leukemia Group B Study (CALGB 10102) Abst 838. In: ASH Annual Meeting; 2009.
31. Cruz RI, et al. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leuk Lymphoma. 2007;48(12):2424-36. (Pubitemid 350253475)
32. Thorson JS, Sievers EL, Ahlert J, et al. Understanding and exploiting natures chemical arsenal: the past, present and future of calicheamicin research; 2000
33. Advani A, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085-93.
34. Kantarjian H, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403-11.
35. Kebriaei P, et al. Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk. 2013;13(3):296-301.
36. O'Brien S, Thomas D, Jorgensen JL, et al. Experience with 2 dose schedules of inotuzumab ozogamicin, single dose, and weekly, in refractory-relapsed acute lymphocytic leukemia (ALL) Abst 671. In: ASH Annual Meeting; 2012.
37. Kantarjian H, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15):2728-36.
38. Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011;17(20):6398-405.
39. Wayne AS, et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res. 2010;16(6):1894-903.
40. Wayne AS, Bhojwani D, Silverman LB, et al. Novel anti-CD22 immunotoxin, moxetumomab pasudotox: phase I study in pediatric acute lymphoblastic leukemia. Abst 248. In: ASH Annual Meeting; 2011.
41. Herrera L, et al. A phase 1 study of combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2009;31(12):936-41. doi:10.1097/MPH.0b013e3181bdf211.
42. Chevallier P, Bodet-Milin C, Robillard N, Eugene T, Kraeber-Bodere F. BCR-ABL1 molecular remission after 90y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph + BALL: a potential new treatment paradigm. Abst 3910. In: ASH Annual Meeting; 2013.
43. Park JH, Brentjens R. Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med. 2010.
44. Park JH, Sauter C, Brentjens R. Cellular therapies in acute lymphoblastic leukemia. Hematol Oncol Clin N Am. 2011;25(6):1281-301.
45. Brentjens RJ, et al. CD19-targeted t cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.
46. Grupp SA, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-18.
47. Grupp SA, Frey NV, et al. Acute lymphoblastic leukemia: therapy, excluding transplantation: novel immune-based therapies and novel targets Abst 67. In: ASH Annual Conference; 2013.
48. .• Lee DW III, Shah NN, et al. Anti-CD19 Chimeric Antigen Receptor (CAR) T cells produce complete responses with acceptable toxicity but without chronic B-cell aplasia in children with relapsed or refractory acute lymphoblastic leukemia (ALL) even after allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Abst 68. In: ASH Annual Meeting; 2013. Emerging Therapy CAR.
49. .• Davila ML, Riviere I, Wang X, et al. Acute lymphoblastic leukemia: therapy, excluding transplantation: novel immune-based therapies and novel targets Abst 69. In: ASH Annual Meeting; 2013. Emerging Therapy CAR.
50. Haso W, et al. Anti-CD22-chimeric antigen receptors targeting Bcell precursor acute lymphoblastic leukemia. Blood. 2013;121(7):1165-74.